Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Freeline

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

Sangamo’s first gene-editing trial doesn’t convince investors

Market spooked by inconclusive early results

- PMLiVE

DNA damage specialists Artios Pharma raises $84m

Team behind development of Lynparza focus on next-gen DDR inhibitors

- PMLiVE

Vernalis accepts £33m takeover offer from Ligand Pharma

Biotech buyout brings team of 70 scientists in Cambridge, UK

- PMLiVE

Spark sputters on haemophilia A gene therapy safety scare

Investors compare data unfavourably with BioMarin rival

Regeneron and Bluebird sign $100m cell therapies deal

Six targets chosen from TCR and other cell therapy platforms

- PMLiVE

Bluebird’s first gene therapy gets European fast track

For once, Europe set for approval and launch ahead of US

Novartis day

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

A round up from pharma, biotech and healthcare

- PMLiVE

Christina Coughlin to leave Immunocore for Tmunity

UPenn pioneers building their own biotech company

- PMLiVE

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

Final European approval around the corner - but reimbursement and specialist centres among outstanding issues

- PMLiVE

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

New funding will help London build on its gene therapy expertise

- PMLiVE

Freeline raises £88m to accelerate haemophilia gene therapy

Spin-out from London university joins fast-developing field

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links